



Patent Application  
Attorney Docket No. PC23164A

1614  
ifw

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 17th day of May, 2004.

By

(Signature of person signing Certificate)  
Kristina L. Konstas

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Jaymin C. Shah :

APPLICATION SERIAL NO.: 10/690,078 : Examiner: Not Yet Assigned

FILING DATE: October 21, 2003 : Group Art Unit: 1614

TITLE: NOVEL INJECTABLE DEPOT  
FORMULATIONS :

MAIL STOP: DD

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of form PTO-FB-A820 which lists the following references cited by the applicants, copies of which are enclosed:

1. EP 1 269 994 A January 2, 2003;
2. WO 02 074200 A September 26, 2002;
3. DANIEL et al., "Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial" PSYCHOPHARMACOLOGY vol. 155, no. 2, May 2001;
4. WO 97 41896 A November 13, 1997;
5. WO 00 72847 A December 7, 2000;
6. US 6,232,304 B1, YESOOK KIM et al.; May 15, 2001;
7. YESOOK KIM et al., "Inclusion complexation of ziprasidone mesylate with  $\beta$ -cyclodextrin sulfobutyl Ether" JOURNAL OF PHARMACEUTICAL SCIENCES vol. 87, no. 12, pages 1560-67, December 1998;

8. A. HATEFI and B. AMSDEN, "Biodegradable injectable in situ forming drug delivery systems" JOURNAL OF CONTROLLED RELEASE vol. 80, pages 9-28, 2002;
9. YIE W. CHIEN, "Long-acting parenteral drug formulations" JOURNAL OF PARENTERAL SCIENCE & TECHNOLOGY, vol. 35, No. 3, May-June 1981.

Above references 1-5 are listed in the International Search Report issued by the Patent Cooperation Treaty (PCT) in relation to PCT/IB 03/04576, which corresponds to the subject application. A copy of said International Search Report is also enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date:

May 17, 2004



Kristina L. Konstas  
Attorney for Applicant(s)  
Reg. No. 37,864

Pfizer Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212)733 -6380

8. A. HATEFI and B. AMSDEN, "Biodegradable injectable in situ forming drug delivery systems" JOURNAL OF CONTROLLED RELEASE vol. 80, pages 9-28, 2002;
9. YIE W. CHIEN, "Long-acting parenteral drug formulations" JOURNAL OF PARENTERAL SCIENCE & TECHNOLOGY, vol. 35, No. 3, May-June 1981.

Above references 1-5 are listed in the International Search Report issued by the Patent Cooperation Treaty (PCT) in relation to PCT/IB 03/04576, which corresponds to the subject application. A copy of said International Search Report is also enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,


Date:

May 17, 2004



Kristina L. Konstas  
Attorney for Applicant(s)  
Reg. No. 37,864

Pfizer Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212)733 -6380



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										ATTY. DOCKET NO. PC23164A					SERIAL NO. 10/690,078				
										APPLICANT Jaymin C. Shah									
										FILING DATE October 21, 2003					GROUP 1614				
<b>U.S. PATENT DOCUMENTS</b>																			
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME			CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
		6	2	3	2	3	0	4	5/15/01	Yesook Kim et al.									
<b>FOREIGN PATENT DOCUMENTS</b>																			
		DOCUMENT NUMBER							DATE	COUNTRY		CLASS	SUBCLASS	TRANSLATION YES NO					
		1	2	6	9	9	9	4	1/2/03	EPO									
		02	0	7	4	2	0	0	9/26/02	WO									
		97	0	4	1	8	9	6	11/13/97	WO									
		00	0	7	2	8	4	7	12/7/00	WO									
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>																			
		DANIEL et al., "Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial" PSYCHOPHARMACOLOGY vol. 155, no. 2, May 2001																	
		YESOOK KIM et al., "Inclusion complexation of ziprasidone mesylate with $\beta$ -cyclodextrin sulfobutyl ether" JOURNAL OF PHARMACEUTICAL SCIENCES vol. 87, no. 12, pages 1560-67, December 1998																	
		A. HATEFI & B. AMSDEN, "Biodegradable injectable in situ forming drug delivery systems" JOURNAL OF CONTROLLED RELEASE vol. 80, pages 9-28, 2002																	
		YIE W. CHIEN, "Long-acting parenteral drug formulations" JOURNAL OF PARENTERAL SCIENCE & TECHNOLOGY, vol. 35, No. 3, May-June 1981																	
EXAMINER										DATE CONSIDERED									
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																			